The Parkinson's Disease market is set to continue to grow over the next 7 years, reaching over $2.37 billion in 2013, a 39% increase from 2006 levels. Combinations, reformulations, and indication expansions will drive the majority of this growth, with key brands expected to be Novartis/Orion's Stalevo, GlaxoSmithKline's (GSK's) Requip Modutab, and UCB-Schwarz's Neupro.
Scope
Analysis of patient potential, unmet needs and clinical trial design in Parkinson's Disease
Overview of key marketed brands, late- and early-stage pipeline drugs, and cell/gene therapies.
Indication- and country-specific sales volume and value forecasts to 2016 of marketed brands, generics, and key late-stage pipeline drugs.
Identification of future market events that are expected to affect Parkinson's Disease drug revenues.
Report Highlights GSK's Requip Modutab will become the market leading Parkinson's Disease brand in 2011. It will be intuitive for prescribers to believe that sustained activation of dopamine receptors with Requip Modutab could have a significant clinical benefit over pulsed agonism with standard drugs.
New pipeline drugs will need to be innovative to compete in an increasingly crowded market. While this is evident in Eisai's E2007, it is lacking in Merck-Serono/Newron's safinamide.
Early studies with cell/gene therapies show great promise for significantly slowing the progression of the disease. However, these alternative approaches will not significantly impact the sales of pharmaceuticals over the forecast period 20072016.
Reasons to Purchase
Benchmark key late-stage Parkinson's Disease compounds against current market leading brands.
Assess country-specific (US, Japan, France, Germany, Italy, Spain and the UK) sales forecasts of key late-stage pipeline drugs and marketed brands.
Understand unmet needs and opportunities in the Parkinson's Disease market based on key opinion leader comments.
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
